266 related articles for article (PubMed ID: 32907924)
1. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
Verschraegen CF; Jerusalem G; McClay EF; Iannotti N; Redfern CH; Bennouna J; Chen FL; Kelly K; Mehnert J; Morris JC; Taylor M; Spigel D; Wang D; Grote HJ; Zhou D; Munshi N; Bajars M; Gulley JL
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32907924
[TBL] [Abstract][Full Text] [Related]
2. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
Guigay J; Lee KW; Patel MR; Daste A; Wong DJ; Goel S; Gordon MS; Gutierrez M; Balmanoukian A; Le Tourneau C; Mita A; Vansteene D; Keilholz U; Schöffski P; Grote HJ; Zhou D; Bajars M; Penel N
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663640
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
4. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
[TBL] [Abstract][Full Text] [Related]
5. Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
Larkin J; Oya M; Martignoni M; Thistlethwaite F; Nathan P; Ornstein MC; Powles T; Beckermann KE; Balar AV; McDermott D; Gupta S; Philips GK; Gordon MS; Uemura H; Tomita Y; Wang J; Michelon E; di Pietro A; Choueiri TK
Oncologist; 2023 Apr; 28(4):333-340. PubMed ID: 36576173
[TBL] [Abstract][Full Text] [Related]
6. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
7. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort.
Levy S; Aarts MJB; Eskens FALM; Keymeulen KBMI; Been LB; Grünhagen D; van Akkooi A; Jalving M; Tesselaar MET
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32948651
[TBL] [Abstract][Full Text] [Related]
8. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.
Galffy G; Lugowska I; Poddubskaya EV; Cho BC; Ahn MJ; Han JY; Su WC; Hauke RJ; Dyar SH; Lee DH; Serwatowski P; Estelles DL; Holden VR; Kim YJ; Vladimirov V; Horvath Z; Ghose A; Goldman A; di Pietro A; Wang J; Murphy DA; Alhadab A; Laskov M
ESMO Open; 2023 Jun; 8(3):101173. PubMed ID: 37141847
[TBL] [Abstract][Full Text] [Related]
9. Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
Reck M; Barlesi F; Yang JC; Westeel V; Felip E; Özgüroğlu M; Dols MC; Sullivan R; Kowalski DM; Andric Z; Lee DH; Sezer A; Hu P; Wang X; von Heydebreck A; Jacob N; Mehr KT; Park K
J Thorac Oncol; 2024 Feb; 19(2):297-313. PubMed ID: 37748693
[TBL] [Abstract][Full Text] [Related]
10. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Xiong H; Guezel G; Nghiem PT
ESMO Open; 2021 Dec; 6(6):100290. PubMed ID: 34715570
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.
Walker JW; Lebbé C; Grignani G; Nathan P; Dirix L; Fenig E; Ascierto PA; Sandhu S; Munhoz R; Benincasa E; Flaskett S; Reed J; Engelsberg A; Hariharan S; Kasturi V
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32269140
[TBL] [Abstract][Full Text] [Related]
12. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
Haanen JBAG; Larkin J; Choueiri TK; Albiges L; Rini BI; Atkins MB; Schmidinger M; Penkov K; Michelon E; Wang J; Mariani M; di Pietro A; Motzer RJ
ESMO Open; 2023 Jun; 8(3):101210. PubMed ID: 37104931
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Uemura H; Albiges L; Fujii Y; Umeyama Y; Wang J; Mariani M; Schmidinger M
ESMO Open; 2022 Apr; 7(2):100450. PubMed ID: 35397432
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T; Nakano Y; Hongo F; Katano H; Miyagawa T; Ueda K; Azuma H; Nozawa M; Hinata N; Hori J; Otoshi T; Shimizu N; Aizawa M; Osada S; Matsui A; Oya M; Eto M; Tomita Y; Shinohara N; Uemura H
Int J Urol; 2024 Mar; 31(3):265-272. PubMed ID: 38110838
[TBL] [Abstract][Full Text] [Related]
15. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H
Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108
[TBL] [Abstract][Full Text] [Related]
16. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
[TBL] [Abstract][Full Text] [Related]
17. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
Nghiem P; Bhatia S; Lipson EJ; Sharfman WH; Kudchadkar RR; Brohl AS; Friedlander PA; Daud A; Kluger HM; Reddy SA; Boulmay BC; Riker AI; Burgess MA; Hanks BA; Olencki T; Margolin K; Lundgren LM; Soni A; Ramchurren N; Church C; Park SY; Shinohara MM; Salim B; Taube JM; Bird SR; Ibrahim N; Fling SP; Homet Moreno B; Sharon E; Cheever MA; Topalian SL
J Clin Oncol; 2019 Mar; 37(9):693-702. PubMed ID: 30726175
[TBL] [Abstract][Full Text] [Related]
18. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Ramalingam SS; Thara E; Awad MM; Dowlati A; Haque B; Stinchcombe TE; Dy GK; Spigel DR; Lu S; Iyer Singh N; Tang Y; Teslenko I; Iannotti N
Cancer; 2022 Jan; 128(1):65-74. PubMed ID: 34478166
[TBL] [Abstract][Full Text] [Related]
19. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
Choueiri TK; Motzer RJ; Rini BI; Haanen J; Campbell MT; Venugopal B; Kollmannsberger C; Gravis-Mescam G; Uemura M; Lee JL; Grimm MO; Gurney H; Schmidinger M; Larkin J; Atkins MB; Pal SK; Wang J; Mariani M; Krishnaswami S; Cislo P; Chudnovsky A; Fowst C; Huang B; di Pietro A; Albiges L
Ann Oncol; 2020 Aug; 31(8):1030-1039. PubMed ID: 32339648
[TBL] [Abstract][Full Text] [Related]
20. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
Strauss J; Deville JL; Sznol M; Ravaud A; Maruzzo M; Pachynski RK; Gourdin TS; Maio M; Dirix L; Schlom J; Donahue RN; Tsai YT; Wang X; Vugmeyster Y; Beier F; Seebeck J; Schroeder A; Chennoufi S; Gulley JL
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37236636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
